Healthcare / BiotechnologyNasdaqCM
$0.77
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 25% · confianza 25%
FCF escenarios
weak_data · normalized FCF n/d · quality 50.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
2/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$28M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-597.6%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2017–2025 · 8 años de histórico normalizado
Revenue CAGR
+19.2%
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.1M · net income $-7.4M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||
| Revenue | $3.1M | $3.1M | $3.5M | $2.9M | $2.9M | $2.4M | $1.6M | $1.7M | $1.3M | $758420.00 |
| Net Income | $-7.4M | $-7.4M | $-5.8M | $-6.8M | $-9.7M | $-13.1M | $-9.3M | $-8.3M | $-5.7M | $-2.1M |
| EPS | -0.23 | -0.23 | -0.20 | -0.24 | -0.34 | -0.47 | — | — | — | — |
| Operating Margin | -232.8% | -232.8% | -168.8% | -283.9% | -346.9% | -612.7% | -625.9% | -552.2% | -586.1% | -939.7% |
| Net Margin | -238.3% | -238.3% | -166.2% | -234.4% | -332.2% | -543.7% | -582.1% | -494.2% | -439.4% | -281.6% |
| Returns | ||||||||||
| ROE | -597.6% | -597.6% | -235.2% | -115.6% | -87.8% | -71.1% | -32.8% | -23.2% | -13.4% | -4.3% |
| Growth & Yield | ||||||||||
| Revenue Growth | -11.6% | -11.6% | 20.6% | -1.1% | 21.9% | 50.1% | -4.7% | 29.8% | 70.8% | — |
| EPS Growth | -15.0% | -15.0% | 16.7% | 29.4% | 27.7% | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.